Q1 EPS Estimates for Eton Pharmaceuticals Raised by B. Riley

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Research analysts at B. Riley increased their Q1 2025 EPS estimates for Eton Pharmaceuticals in a research note issued to investors on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will earn $0.13 per share for the quarter, up from their previous estimate of $0.06. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.

A number of other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $16.49 on Wednesday. Eton Pharmaceuticals has a one year low of $3.18 and a one year high of $18.41. The stock has a 50-day moving average price of $14.11 and a 200 day moving average price of $13.11. The company has a market capitalization of $442.23 million, a P/E ratio of -74.95 and a beta of 1.34.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings data on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%. The company had revenue of $11.65 million during the quarter, compared to analysts’ expectations of $10.53 million.

Institutional Trading of Eton Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of ETON. Mink Brook Asset Management LLC bought a new stake in shares of Eton Pharmaceuticals in the 4th quarter valued at approximately $6,071,000. Cannell Capital LLC bought a new stake in Eton Pharmaceuticals during the fourth quarter valued at $5,079,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Eton Pharmaceuticals by 230.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company’s stock worth $2,862,000 after purchasing an additional 149,864 shares during the period. Millennium Management LLC bought a new position in shares of Eton Pharmaceuticals in the 4th quarter worth about $1,850,000. Finally, Nantahala Capital Management LLC boosted its holdings in shares of Eton Pharmaceuticals by 12.0% in the 4th quarter. Nantahala Capital Management LLC now owns 1,118,483 shares of the company’s stock valued at $14,898,000 after buying an additional 119,750 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.